Square Pharmaceuticals Sustainability Profile
Square Pharmaceuticals Limited, headquartered in Dhaka, Bangladesh, stands as a leading entity in the pharmaceutical industry. Founded in 1985, the company has established a robust presence across South Asia, focusing on the development, manufacturing, and marketing of a diverse range of pharmaceutical products. With a commitment to quality and innovation, Square Pharmaceuticals offers a wide array of medications, including prescription drugs, over-the-counter products, and herbal medicines. Their unique formulations and adherence to international standards have positioned them as a trusted name in healthcare. Recognised for their significant contributions to the industry, Square Pharmaceuticals has achieved numerous accolades, solidifying its market position as one of the top pharmaceutical companies in Bangladesh. Their dedication to research and development continues to drive advancements in healthcare solutions.
DitchCarbon Score
How does Square Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Square Pharmaceuticals's score of 25 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Square Pharmaceuticals's reported carbon emissions
In 2024, Square Pharmaceuticals, headquartered in Bangladesh (BD), reported total carbon emissions of approximately 60,000,000 kg CO2e from Scope 1 and about 4,387,000 kg CO2e from Scope 2. This data reflects the company's direct and indirect emissions associated with its operations. Notably, there is no reported data for Scope 3 emissions. Square Pharmaceuticals has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The emissions data is cascaded from its parent company, Square Pharmaceuticals PLC., which provides a broader context for understanding its environmental impact. As a current subsidiary, Square Pharmaceuticals is part of a larger corporate family that may influence its climate strategies and initiatives. However, without specific reduction initiatives or targets disclosed, the company's commitment to addressing climate change remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 59,705,000 |
| Scope 2 | 4,387,000 |
| Scope 3 | - |
How Carbon Intensive is Square Pharmaceuticals's Industry?
How Carbon Intensive is Square Pharmaceuticals's Location?
Square Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Square Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.